PHARMATIS-SAS listed on Inc Ransom leak site

• Ransomware group: Inc Ransom
• Country: France
• Sector: Healthcare
• Announcement date: November 15, 2024

Inc Ransom claims data breach at PHARMATIS-SAS

The Inc Ransom ransomware group has listed the French-based pharmaceutical company PHARMATIS-SAS on its dedicated leak site. The announcement, which was created on November 15, 2024, indicates that the threat actor group claims to possess data belonging to the organization. As part of their typical operations, the group has suggested that they may release the stolen data publicly if their demands are not met.

Ransomware leak sites serve as a platform for cybercriminals to exert pressure on their victims through public shaming. In many modern cyberattacks, threat actors employ a tactic known as double extortion. In this scenario, attackers do not merely encrypt an organization's systems to disrupt operations; they also exfiltrate sensitive information before the encryption occurs. By threatening to leak this data on a public forum, the attackers aim to increase the pressure on the victim to pay the ransom, leveraging the potential for reputational damage, regulatory fines, and loss of competitive advantage.

Details of the claimed data theft

While the specific volume of the stolen data and the exact ransom amount have not been disclosed by the group, the announcement includes evidence of the breach. The group has provided screenshots intended to prove the validity of their claims. These samples include various documents that highlight the internal information they have allegedly acquired.

According to the information provided in the leak site announcement, the following types of data are involved in the claim:

• Corporate organizational chart
• Technical documents
• Corporate documents

The presence of such documents suggests that the attackers have gained access to internal structural and technical information regarding the company's operations.

About PHARMATIS-SAS

PHARMATIS-SAS is a company operating within the pharmaceutical sector, headquartered in France. The firm provides a wide range of services, including product development, technical consulting, and full-service solutions. The organization is recognized for its commitment to environmentally conscious policies and holds ISO 14001 certification. PHARMATIS-SAS is known for offering personalized support to its various clients through its specialized service offerings.

Potential risks and implications

This incident presents a significant risk of exposure for sensitive corporate data within PHARMATIS-SAS. Because the company operates within the pharmaceutical industry, the leaked information could potentially include highly sensitive data related to intellectual property or trade secrets. Such information is often critical to a company's competitive standing and market value.

Furthermore, since the entity is based in France, this incident may lead to legal consequences regarding data protection obligations under the General Data Protection Regulation (GDPR). Organizations operating in the European Union must adhere to strict protocols regarding the handling and protection of personal data, and breaches can trigger significant regulatory scrutiny.

Beyond the immediate data exposure, the use of double-extortion tactics by groups like Inc Ransom creates secondary operational risks. When corporate documents and organizational charts are leaked, it can expose employees and business partners to targeted phishing attacks. Attackers can use the stolen information to craft highly convincing social engineering campaigns, impersonating colleagues or partners to further compromise the network or steal credentials.

To mitigate such risks, organizations in the healthcare and pharmaceutical sectors often implement defensive measures such as robust encryption, multi-factor authentication, and continuous monitoring of network traffic. Maintaining strict access controls and conducting regular security awareness training for employees are also vital components of a comprehensive cybersecurity posture designed to defend against the evolving tactics of ransomware groups.